suPAR is a biomarker and therapeutic target for AKI

More Details

More Details

Catalytic iron is a biomarker

and therapeutic target in AKI

More Details

A common genetic variant in HO-1 predicts risk of AKI following cardiac surgery

More Details

Immune checkpoint inhibitors cause AKI through tubulo-interstitial nephritis

More Details

FGF23 is an early marker of AKI and death after cardiac surgery and in critically ill patients.

Research

An overview of our projects

Publications

A portfolio with a list of our publications

Bio

Get to know more about the PI

Team

Get to know more about our team

The Leaf Lab conducts patient-oriented research in acute kidney injury (AKI) and critical illness. Our goal is to develop novel approaches to prevent AKI, and to improve outcomes in patients who suffer from AKI. Read more about AKI.

Our research is highly collaborative and interdisciplinary and includes:

•  Randomized trials
•  Biomarker studies
•  Genetics
•  Epidemiology

News

Upcoming Talks

March, 2022
David Leaf will be giving Renal Grand Rounds on STOP-COVID at NYU and Montefiore Medical Center.

NIH K23 Grant

January, 2022
Shruti Gupta was awarded a K23 Career Development Award from the NIH/NIDDK for her proposal, “Novel Pathways and Therapeutic Targets for Cisplatin-Associated Acute Kidney Injury.”

American Society of Onconephrology

December, 2021
Shruti Gupta is the Founder and first President of the American Society of Onconephrology!

Match Day

December 1, 2021
Congratulations to Robert Hayden for matching at the BWH/MGH Joint Nephrology Fellowship Program.

Oral Abstract and Publication

November 4, 2021
Shruti Gupta’s abstract entitled, “Acute Kidney Injury in Patients Treated with Immune Checkpoint Inhibitors” was presented as an oral abstract at ASN Kidney Week, and was published in J Immunother Cancer.

Top Paper Award

January 27, 2021
Shruti Gupta’s paper entitled, “AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19” was selected as one of the top 5 original research papers published in J Am Soc Nephrol in 2020.

NIH R01 Grant

September 1, 2020
David Leaf was awarded an R01 grant from the NIH/NIDDK for his proposal entitled, “Deferoxamine for the Prevention of Acute Kidney Injury.” The grant is funding DEFEAT-AKI, a phase II, multicenter, randomized, double-blind, placebo-controlled trial of iron chelation with deferoxamine for prevention of cardiac surgery-associated AKI.

NIH R01 Grant

May 1, 2019
David Leaf was awarded an R01 grant from the NIH/NHLBI for his proposal entitled, “Precision Medicine Approach to Vitamin D3 Administration in Critically Ill Patients.”